Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15898926 | 0.82 | KMT2A (0.41) | KMT2AGAANR1H2CYP1A2CNR1 | |
| SCHEMBL11283178 | 0.81 | GAA (0.44) | KMT2AGAANR1H2CYP1A2TP53 | |
| SCHEMBL3213738 | 0.76 | PTGER1 (0.48) | CYP1A2TP53ALDH1A1 | |
| SCHEMBL1234127 | 0.75 | AURKA (0.52) | KMT2AGAACYP1A2TP53MAPT | |
| SCHEMBL31459254 | 0.73 | GAA (0.48) | KMT2AGAANR1H2CYP1A2TP53 | |
| SCHEMBL3344116 | 0.72 | KMT2A (0.44) | KMT2AGAACYP1A2TP53MAPT | |
| SCHEMBL1197227 | 0.72 | LMNA (0.58) | KMT2AGAACYP1A2TP53MAPT | |
| SCHEMBL21964570 | 0.71 | NR1H2 (0.51) | KMT2AGAANR1H2CYP1A2MAPT | |
| SCHEMBL20723202 | 0.71 | KDM4E (0.43) | KMT2AGAACYP1A2MAPTPOLB | |
| SCHEMBL20723221 | 0.71 | KDM4E (0.43) | KMT2AGAACYP1A2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | KMT2A 772/4885GAA 4215/4885NR1H2 858/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | KMT2A 897/4885GAA 4042/4885NR1H2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.